Franklin Resources Inc. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,896,086 shares of the biopharmaceutical company's stock after selling 27,016 shares during the period. Franklin Resources Inc. owned 1.73% of Regeneron Pharmaceuticals worth $1,912,695,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. International Assets Investment Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth $127,489,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Regeneron Pharmaceuticals by 23.8% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock valued at $525,804,000 after purchasing an additional 96,266 shares in the last quarter. TD Asset Management Inc raised its position in Regeneron Pharmaceuticals by 30.4% in the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company's stock valued at $369,484,000 after purchasing an additional 82,034 shares during the period. Finally, Icon Wealth Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock worth $79,874,000 after purchasing an additional 75,569 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.
Regeneron Pharmaceuticals Trading Down 1.3 %
NASDAQ REGN traded down $9.67 on Friday, hitting $731.30. 684,706 shares of the stock were exchanged, compared to its average volume of 556,078. The company's 50-day moving average price is $855.40 and its two-hundred day moving average price is $1,005.56. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 52-week low of $728.68 and a 52-week high of $1,211.20. The company has a market capitalization of $80.36 billion, a price-to-earnings ratio of 18.34, a P/E/G ratio of 2.32 and a beta of 0.08.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on REGN shares. Cantor Fitzgerald reiterated a "neutral" rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price target on the stock. Finally, Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $1,099.90.
Check Out Our Latest Report on Regeneron Pharmaceuticals
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Further Reading
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
